SML2983

Vandetanib

≥98% (HPLC)

• Synonim(y): N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinamine, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine, ZD6474
• Wzór empiryczny (zapis Hilla): C₂₂H₂₄BrFN₄O₂
• Numer CAS: 443913-73-3
• Masa cząsteczkowa: 475.35
• UNSPSC Code: 12352200
• NACRES: NA.77
• MDL number: MFCD07772346
• Assay: ≥98% (HPLC)
• Form: powder
• Quality level: 100

Właściwości

• SMILES string: Fc1c(ccc(c1)Br)Nc2ncnc3c2cc(c(c3)OCC4CCN(CC4)C)OC
• InChI: 1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)
• InChI key: UHTHHESEBZOYNR-UHFFFAOYSA-N
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: 2-8°C
• Quality Level: 100

Opis

Biochem/physiol Actions

Orally active, selective inhibitor of VEGF receptor kinase activity; also inhibits EGFR and RET tyrosine kinases

Vandetanib is an orally active and potent inhibitor of vascular endothelial growth factor receptor receptor 2 (VEGFR2) kinase activity that is used to treat medullary thyroid cancer. Vandetanib also inhibits epidermal growth factor receptor (EGFR), and RET tyrosine kinases.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• pictograms: GHS08,GHS07,GHS09
• signalword: Warning
• hcodes: H302,H361d,H373,H410
• pcodes: P202 - P260 - P264 - P273 - P301 + P312 - P308 + P313
• Hazard Classifications: Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 2 - STOT RE 2
• target_organs: Gastrointestinal tract
• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable